Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

Anti-Human CD160 Antibody (H7)

Catalog #:   FHB80810 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG1, kappa
Applications: FCM
Accession: O95971
Overview

Catalog No.

FHB80810

Species reactivity

Human

Host species

Mouse

Isotype

IgG1, kappa

Clonality

Monoclonal

Conjugation

Unconjugated

Target

Natural killer cell receptor BY55, CD160 antigen, CD160, BY55

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

O95971

Applications

FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

H7

Data Image
  • Bioactivity
    Detects Human CD160 in indirect ELISAs.
  • Flow-cytometry
    Flow-cytometry using anti-human CD160 antibody.CD160 Transfected CHO cells were stained with an irrelevant antibody (Blue Histogram) or an anti-human CD160 antibody monoclonal antibody (Catalog # FHB80810 ,Green Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a FITC conjugated goat anti-mouse antibody (Catalog # PMB96441) and cells analysed on a NovoCyte Flow Cytometer.
References

Ex vivo sensitivity to broadly neutralizing antibodies and anti-CD4 antibody UB-421 of infectious viral isolates from people living with multidrug-resistant HIV., PMID:38728839

Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications., PMID:38360636

Combination of oligo-fractionated irradiation with nivolumab can induce immune modulation in gastric cancer., PMID:38290769

Linking donor-specific antibody generation with natural killer cells in antibody-mediated kidney graft rejection., PMID:37739612

Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy., PMID:37649037

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment., PMID:37345056

Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors., PMID:37230538

Interleukin-21 promotes Type-1 activation and cytotoxicity of CD56dimCD16bright natural killer cells during kidney allograft antibody-mediated rejection showing a new link between adaptive and innate humoral allo-immunity., PMID:37220805

BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM., PMID:36081508

Realigning the LIGHT signaling network to control dysregulated inflammation., PMID:35604387

Immune features of COVID-19 convalescent individuals revealed by a single-cell RNA sequencing., PMID:35453072

The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma., PMID:35428910

Changes in the natural killer cell repertoire and function induced by the cancer immune adjuvant candidate IMMUNEPOTENT-CRP., PMID:35381435

Expression Profile and Biological Role of Immune Checkpoints in Disease Progression of HIV/SIV Infection., PMID:35336991

Attenuation of the BTLA/HVEM Regulatory Network in the Circulation in Primary Sjögren's Syndrome., PMID:35159987

Interacting Genetic Lesions of Melanoma in the Tumor Microenvironment: Defining a Viable Therapy., PMID:34888847

Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity., PMID:34888843

A novel 10-gene immune-related lncRNA signature model for the prognosis of colorectal cancer., PMID:34814366

Distinct Molecular Subtypes of Diffuse Large B Cell Lymphoma Patients Treated with Rituximab-CHOP Are Associated with Different Clinical Outcomes and Molecular Mechanisms., PMID:34250086

A proportion of CD4+ T cells from patients with chronic Chagas disease undergo a dysfunctional process, which is partially reversed by benznidazole treatment., PMID:33539379

Combining phage display with SMRTbell next-generation sequencing for the rapid discovery of functional scFv fragments., PMID:33382949

A primer set for the rapid isolation of scFv fragments against cell surface antigens from immunised rats., PMID:33154441

CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models., PMID:32363119

Soluble Fc-Disabled Herpes Virus Entry Mediator Augments Activation and Cytotoxicity of NK Cells by Promoting Cross-Talk between NK Cells and Monocytes., PMID:30770415

Monocytes of Different Subsets in Complexes with Platelets in Patients with Myocardial Infarction., PMID:30300910

[A Preliminary Study on the Expression of CD160 on NK Cells and Its Mechanism of Mediating NK Killing Effect]., PMID:30295284

Ox40 regulates the conversion and suppressive function of double-negative regulatory T cells., PMID:30268799

Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models., PMID:29860455

ADCC-Mediated CD56DIM NK Cell Responses Are Associated with Early HBsAg Clearance in Acute HBV Infection., PMID:29541698

Associations between HVEM/LIGHT/BTLA/CD160 polymorphisms and the occurrence of antibody-mediate rejection in renal transplant recipients., PMID:29245962

A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator., PMID:29061848

Antibodies targeting BTLA or TIM-3 enhance HIV-1 specific T cell responses in combination with PD-1 blockade., PMID:28882621

Mechanistic Sharing Between NK Cells in ABMR and Effector T Cells in TCMR., PMID:28654216

PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells., PMID:28588576

Evidence for CD16a-Mediated NK Cell Stimulation in Antibody-Mediated Kidney Transplant Rejection., PMID:27906829

Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier., PMID:27702550

Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis., PMID:27605882

Increased Heterologous Protein Expression in Drosophila S2 Cells for Massive Production of Immune Ligands/Receptors and Structural Analysis of Human HVEM., PMID:26202493

Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations., PMID:25965355

T cells Exhibit Reduced Signal Transducer and Activator of Transcription 5 Phosphorylation and Upregulated Coinhibitory Molecule Expression After Kidney Transplantation., PMID:25769075

Genes associated with antibody-dependent cell activation are overexpressed in renal biopsies from patients with antibody-mediated rejection., PMID:25449536

Interleukin-22 and CD160 play additive roles in the host mucosal response to Clostridium difficile infection in mice., PMID:25327211

CD160 isoforms and regulation of CD4 and CD8 T-cell responses., PMID:25179432

[CD160 characterization and its association with disease progression in patients with chronic HIV-1 infection]., PMID:25146744

CD8 T cell memory to a viral pathogen requires trans cosignaling between HVEM and BTLA., PMID:24205056

PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads., PMID:24204962

Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors., PMID:24148617

Rapid perturbation in viremia levels drives increases in functional avidity of HIV-specific CD8 T cells., PMID:23853580

CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival., PMID:23593209

Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-γ-producing cells., PMID:23453631

Datasheet
$ 225
Product specifications
50 μg 225 100 μg 372

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Human CD160 Antibody (H7) [FHB80810]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only